302 related articles for article (PubMed ID: 33143664)
21. Establishment of a human ovarian clear cell carcinoma cell line mutant in PIK3CB but not PIK3CA.
Hoshino H; Inoue D; Shinagawa A; Yoshida H; Shigeto S; Matsuda K; Akama TO; Yoshida Y; Kobayashi M
Hum Cell; 2024 Jul; 37(4):1184-1193. PubMed ID: 38573494
[TBL] [Abstract][Full Text] [Related]
22. Establishment and molecular characterization of a human ovarian clear cell carcinoma cell line (FDOV1).
Jiang W; Ye S; Xiang L; Yang W; He T; Pei X; Guo L; Yang H
J Ovarian Res; 2018 Jul; 11(1):58. PubMed ID: 29986747
[TBL] [Abstract][Full Text] [Related]
23. ARID1A mutations in endometriosis-associated ovarian carcinomas.
Wiegand KC; Shah SP; Al-Agha OM; Zhao Y; Tse K; Zeng T; Senz J; McConechy MK; Anglesio MS; Kalloger SE; Yang W; Heravi-Moussavi A; Giuliany R; Chow C; Fee J; Zayed A; Prentice L; Melnyk N; Turashvili G; Delaney AD; Madore J; Yip S; McPherson AW; Ha G; Bell L; Fereday S; Tam A; Galletta L; Tonin PN; Provencher D; Miller D; Jones SJ; Moore RA; Morin GB; Oloumi A; Boyd N; Aparicio SA; Shih IeM; Mes-Masson AM; Bowtell DD; Hirst M; Gilks B; Marra MA; Huntsman DG
N Engl J Med; 2010 Oct; 363(16):1532-43. PubMed ID: 20942669
[TBL] [Abstract][Full Text] [Related]
24. Pten and Dicer1 loss in the mouse uterus causes poorly differentiated endometrial adenocarcinoma.
Wang X; Wendel JRH; Emerson RE; Broaddus RR; Creighton CJ; Rusch DB; Buechlein A; DeMayo FJ; Lydon JP; Hawkins SM
Oncogene; 2020 Oct; 39(40):6286-6299. PubMed ID: 32843721
[TBL] [Abstract][Full Text] [Related]
25. Optimised ARID1A immunohistochemistry is an accurate predictor of ARID1A mutational status in gynaecological cancers.
Khalique S; Naidoo K; Attygalle AD; Kriplani D; Daley F; Lowe A; Campbell J; Jones T; Hubank M; Fenwick K; Matthews N; Rust AG; Lord CJ; Banerjee S; Natrajan R
J Pathol Clin Res; 2018 Jul; 4(3):154-166. PubMed ID: 29659191
[TBL] [Abstract][Full Text] [Related]
26. Clear cell carcinoma of the endometrium: an immunohistochemical and molecular analysis of 45 cases.
Zannoni GF; Santoro A; Angelico G; Spadola S; Arciuolo D; Valente M; Inzani F; Pettinato A; Vatrano S; Fanfani F; Scambia G; Fraggetta F
Hum Pathol; 2019 Oct; 92():10-17. PubMed ID: 31269413
[TBL] [Abstract][Full Text] [Related]
27. Treatment of advanced or recurrent endometrial carcinoma with doxorubicin in patients progressing after paclitaxel/carboplatin: Memorial Sloan-Kettering Cancer Center experience from 1995 to 2009.
Makker V; Hensley ML; Zhou Q; Iasonos A; Aghajanian CA
Int J Gynecol Cancer; 2013 Jun; 23(5):929-34. PubMed ID: 23598889
[TBL] [Abstract][Full Text] [Related]
28. Inactivation of Arid1a in the endometrium is associated with endometrioid tumorigenesis through transcriptional reprogramming.
Suryo Rahmanto Y; Shen W; Shi X; Chen X; Yu Y; Yu ZC; Miyamoto T; Lee MH; Singh V; Asaka R; Shimberg G; Vitolo MI; Martin SS; Wirtz D; Drapkin R; Xuan J; Wang TL; Shih IM
Nat Commun; 2020 Jun; 11(1):2717. PubMed ID: 32483112
[TBL] [Abstract][Full Text] [Related]
29. Therapeutic preferability of gemcitabine for ARID1A-deficient ovarian clear cell carcinoma.
Kuroda T; Ogiwara H; Sasaki M; Takahashi K; Yoshida H; Kiyokawa T; Sudo K; Tamura K; Kato T; Okamoto A; Kohno T
Gynecol Oncol; 2019 Dec; 155(3):489-498. PubMed ID: 31604667
[TBL] [Abstract][Full Text] [Related]
30. Novel molecular profiles of endometrial cancer-new light through old windows.
Doll A; Abal M; Rigau M; Monge M; Gonzalez M; Demajo S; Colás E; Llauradó M; Alazzouzi H; Planagumá J; Lohmann MA; Garcia J; Castellvi S; Ramon y Cajal J; Gil-Moreno A; Xercavins J; Alameda F; Reventós J
J Steroid Biochem Mol Biol; 2008 Feb; 108(3-5):221-9. PubMed ID: 18061438
[TBL] [Abstract][Full Text] [Related]
31. Targeted sequencing with a customized panel to assess histological typing in endometrial carcinoma.
Cuevas D; Valls J; Gatius S; Roman-Canal B; Estaran E; Dorca E; Santacana M; Vaquero M; Eritja N; Velasco A; Matias-Guiu X
Virchows Arch; 2019 May; 474(5):585-598. PubMed ID: 30710169
[TBL] [Abstract][Full Text] [Related]
32. Establishment of a cell line from a neuroendocrine carcinoma of the endometrium and an invasion model.
Yoshida Y; Kamitani N; Sasaki H; Kotsuji F
Anticancer Res; 1998; 18(3A):1569-77. PubMed ID: 9673372
[TBL] [Abstract][Full Text] [Related]
33. Molecular evidence for a clonal relationship between synchronous uterine endometrioid carcinoma and ovarian clear cell carcinoma: a new example of "precursor escape"?
Weng CH; Wu RC; Chen SJ; Chen HC; Tan KT; Lee YS; Huang SS; Yang LY; Wang CJ; Chou HH; Chao AS; Chao A; Lai CH
J Mol Med (Berl); 2021 Jul; 99(7):959-966. PubMed ID: 33768299
[TBL] [Abstract][Full Text] [Related]
34. The ARID1A, p53 and ß-Catenin statuses are strong prognosticators in clear cell and endometrioid carcinoma of the ovary and the endometrium.
Heckl M; Schmoeckel E; Hertlein L; Rottmann M; Jeschke U; Mayr D
PLoS One; 2018; 13(2):e0192881. PubMed ID: 29451900
[TBL] [Abstract][Full Text] [Related]
35. Molecular carcinogenesis of endometrial cancer.
Liu FS
Taiwan J Obstet Gynecol; 2007 Mar; 46(1):26-32. PubMed ID: 17389185
[TBL] [Abstract][Full Text] [Related]
36. Culture characters, genetic background, estrogen/progesterone receptor expression, and tumorigenic activities of frequently used sixteen endometrial cancer cell lines.
Qu W; Zhao Y; Wang X; Qi Y; Zhou C; Hua Y; Hou J; Jiang SW
Clin Chim Acta; 2019 Feb; 489():225-232. PubMed ID: 30107158
[TBL] [Abstract][Full Text] [Related]
37. [Establishment of a new human endometrial adenocarcinoma cell line, Watanabe cells, containing estrogen receptor].
Satoh T; Nishida M; Oki A; Tsunoda H; Kasahara K; Kubo T
Hum Cell; 1995 Dec; 8(4):195-201. PubMed ID: 8721091
[TBL] [Abstract][Full Text] [Related]
38. Establishment of a new human cell line (EN) with TP53 mutation derived from endometrial carcinoma.
Isaka K; Nishi H; Sagawa Y; Nakada T; Osakabe Y; Serizawa H; Ebihara Y; Takayama M
Cancer Genet Cytogenet; 2003 Feb; 141(1):20-5. PubMed ID: 12581894
[TBL] [Abstract][Full Text] [Related]
39. Racial differences in oncogene mutations detected in early-stage low-grade endometrial cancers.
Cote ML; Atikukke G; Ruterbusch JJ; Olson SH; Sealy-Jefferson S; Rybicki BA; Alford SH; Elshaikh MA; Gaba AR; Schultz D; Haddad R; Munkarah AR; Ali-Fehmi R
Int J Gynecol Cancer; 2012 Oct; 22(8):1367-72. PubMed ID: 23013731
[TBL] [Abstract][Full Text] [Related]
40. ARID1A, a factor that promotes formation of SWI/SNF-mediated chromatin remodeling, is a tumor suppressor in gynecologic cancers.
Guan B; Wang TL; Shih IeM
Cancer Res; 2011 Nov; 71(21):6718-27. PubMed ID: 21900401
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
